Tonix制药控股 TNXP 深 沪
等待开盘 07-30 09:30:00 美东时间
42.63
-4.670
-9.87%
华盛通- 最 高47.00
- 今 开46.12
- 成交量 208.87万股
- 最 低 42.62
- 昨 收 47.30
- 总市值 79.67亿
- 52周最高 130.00
- 市盈率 静 --
- 换手率 1.12%
- 52周最低 6.76
- 委 比 4.63%
- 总股本 1.87亿
- 历史最高 13440000000.00
- 量 比 1.31
- 振 幅 9.26%
- 历史最低 15.00
- 每 手 1
- 风险率 5.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
Tonix Pharmaceuticals launched the "Move Fibro Forward" campaign to raise awareness for fibromyalgia, a chronic pain condition with no new FDA-approved treatments in over 15 years. The campaign aims to support individuals impacted by the disease and highlight their experiences. Fibromyalgia affects approximately 10 million adults in the U.S., causing widespread pain, fatigue, and impaired quality of life. Tonix is a biotech company focused on pai...
07-21 11:00
Tonix Pharma Unveils Promising TNX-801 Vaccine Findings
Tonix Pharma ( ($TNXP) ) has provided an update. On July 10, 2025, Tonix Pharma...
07-10 19:28
Tonix Pharma Publishes Phase 3 Trial Results
Tonix Pharma ( ($TNXP) ) just unveiled an announcement. On July 9, 2025, Tonix ...
07-10 04:52
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
Tonix Pharmaceuticals announced the publication of full results from its Phase 3 RESILIENT trial, showing that TNX-102 SL significantly reduced fibromyalgia pain compared to placebo, confirming prior RELIEF trial results. The drug, a non-opioid analgesic, was generally well-tolerated with mild side effects. The FDA has set an August 15, 2025 PDUFA date for review, and if approved, TNX-102 SL would be the first new fibromyalgia treatment in over 1...
07-09 20:01
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
Tonix Pharmaceuticals' TNX-801, a single-dose live virus vaccine candidate, provides durable protection against mpox and other orthopoxviruses in preclinical studies. The vaccine is minimally replicative, well-tolerated in immunocompromised animals, and does not spread to blood or tissues at high doses. Sina Bavari, PhD, will present data on TNX-801's safety, immunogenicity, and efficacy at the Vaccine Congress 2025 in Vienna, with plans to advan...
07-07 11:00
Tonix Pharma Publishes Study on TNX-1700 Efficacy
Tonix Pharma ( ($TNXP) ) has shared an announcement. On July 2, 2025, Tonix Pha...
07-02 19:29
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models
A study published in *Cancer Cell* highlights the potential of TNX-1700, a fusion protein targeting immunosuppressive neutrophils, in enhancing anti-PD-1 immunotherapy for gastric cancer. Mouse models showed that combining mTNX-1700 (murine version) with anti-PD-1 therapy increased survival, reduced metastasis, and activated cancer-killing CD8+ T cells. TNX-1700, developed by Tonix Pharmaceuticals in collaboration with Columbia University, is cur...
07-02 11:00
美國6月非農前瞻：失業率4.3%為7月降息鋪路，美股美債繼續漲？
TradingKey - 2025年7月3日週四，美國勞工統計局將發佈6月非農就業報告，這份就業報告因美國獨立紀念日假期提前一日發佈。分析認為，川普關稅的負面影響將在6月勞動力市場數據體現，聯準會7月降息概率有望增加，利好美股美債等資產表現。據Factset數據，經濟學家預計美國6月非農就業新增人數將從5月的13.9萬人降至11.5萬；失業率將反彈至4.3%，此前已連續三個月穩定在4.2%的水平。
07-02 07:04
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Tonix Pharmaceuticals Holding Corp. has been added to the Russell 3000® and Russell 2000® Indexes, reflecting its growth and development. CEO Seth Lederman highlighted the increased visibility and potential FDA approval of TNX-102 SL for fibromyalgia. Russell indexes, widely used by investors, include over $10.6 trillion in assets. Tonix focuses on therapies for疼痛管理和公共健康挑战，正在推进多个产品线的开发。
06-30 11:00
Tonix Showcases New Fibromyalgia Drug That Targets Sleep and Pain Without Opioids
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) presented data in a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, held June 11-14, 2025, in Barcelona, Spain. A
06-16 19:11
